Amendment of Solicitation/Modification of Contract 0016, dated September 21, 2018, to Agreement, dated May 13, 2011, between the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services and SIGA

1. CONTRACT ID CODE

PAGE OF PAGES

   1 | 2

2 AMENDMENT/MODIFICATION NO.

0016

See Block 16C

OS227396

ASPR-BARDA

200 Independence Ave., S.W.

Room 640-G

Washington DC 20201

ASPR-BARDA

330 Independence Ave, SW, Rm G640

Washington DC 20201

 

 

SIGA TECHNOLOGIES, INC. 35 E 6

35 E 62ND ST

 

HHS0100201100001C

 

 

Code   1385150

 

   The above numbered solicitation is amended as set forth in item 14. The hour and date specified for receipt of Offers is extended. is not extended.

   Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing items 8 and 15, and returning __________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By
separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT
THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by
virtue of this amendment you desire to change an offer already submitted , such change may be made by telegram or letter, provided each telegram or letter makes
reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

See Schedule

A. THIS CHANGE ORDER IS ISSUED PURSUANT TO (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT

 

 

B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes In paying office,
appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

FAR 52.243-2 Changes - Cost Reimbursement and FAR 1.605-1 - Mutual Agreement of the Parties

 

D. OTHER (Specify type of modification and authority)

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

Tax ID Number: 13 ###-###-####

DUNS Number: 932651516

PURPOSE: This modification is to adjust funding under CLIN 0006 and update designated

COR and Alternate COR.

FUNDS ALLOTED PRIOR TO MOD #16 $522,320,688.00

FUNDS REMOVED WITH MOD #16 - $230,902.00

FUNDS ALLOTTED WITH MOD #16 + $230,902.00

TOTAL FUNDS ALLOTED TO DATE $522,320,688.00 (Unchanged)

EXPIRATION DATE: September 24, 2020 (Unchanged)

CONTRACT FUNDED THROUGH September 24, 2020 (Unchanged)

Continued ...

 

15B. CONTRACTOR/OFFEROR

BY /s/ Dennis E. Hruby

(Signature of person authorized to sign.)

15C. DATE SIGNED

20 Sep 2018

16B. UNITED STATES OF AMERICA

BY /s/ Elizabeth Steiner

(Signature of the Contracting Officer.)

9/21/18

REFERENCE NO. OF DOCUMENT BEING CONTINUED

HHSO100201100001C/0016

PAGE OF

2 | 2

NAME OF OFFEROR OR CONTRACTOR

SIGA TECHNOLOGIES, INC. 1385150

 

1) The following revision is made to CLIN 0006 under this modification:

CLIN 0006 is being deobligated in full and then re obligated in full. The amount of
decrease ($230,902) and then increase ($230,902). The total value of this FFP CLIN
is $230,902.00.

2) Update SECTION G, Article G.2. as follows and replace the designated primary COR:

ARTICLE G.2. CONTRACTING OFFICER'S REPRESENTATIVE (COR)

The following Contracting Officer's Representative (COR) will represent the
Government for the purpose of this contract:

Claiborne Hughes Primary COR

Chia-Wei Tsai, PhD Alternate COR

As delegated by the Contracting Officer, the COR is responsible for: (1) monitoring the Contractor's technical progress, including the surveillance and assessment of performance and recommending to the Contracting Officer changes in requirements; (2) assisting the contracting Officer in interpreting the statement of work and any other technical performance requirements; (3) performing technical evaluation as required; (4) performing technical inspections and acceptances required by this contract; and (5) assisting in the resolution of technical problems encountered during performance.

All other terms and conditions of contract HHSO100201100001C remain unchanged.

FOB: Destination

Period of Performance: 06/28/2016 to 09/24/2020

Change Item 1 to read as follows(amount shown is the obligated amount):

Smallpox Antiviral Drug for the Strategic 0.00

National Stockpile CAN 1990001

Accounting Info:

2011.1990001.26402 Appr. Yr.: 2011 CAN: 1990001 Object Class: 26402

Funded: -$230,902.00

Accounting Info:

2016.1992016.25103 Appr. Yr.: 2016 CAN: 1992016 Object Class: 25103

Funded: $0.00

Accounting Info:

2018.199TWNP.26201 Appr. Yr.: 2018 CAN: 199TWNP Object Class: 26201

Funded: $230,902.00